Executives of the Big Three pharma companies involved in diabetes research, development, and manufacturing — Eli Lilly and Co., Novo Nordisk, and Sanofi — spoke publicly this week at JPMorgan’s 2020 Healthcare conference on issues related to insulin pricing and supply.

Last month, the FDA approved the Tandem Diabetes Care update to its t:slim X2 insulin pump Control-IQ technology, clearing the way for the first automated and interoperable insulin dosing system on the U.S. market.

The hybrid system, which automates basal insulin delivery, was tested in a non-clinical setting in this hotel-based study of children between two years of age and just under six years of age.

The 780G trial will evaluate an automated basal-and-bolus insulin delivery system. We provide enrollment info for both trials.